Skip to main content
GLSI
NASDAQ Life Sciences

Greenwich LifeSciences Q3 Loss Widens to $5.8M; Cash Falls to $5.9M With Going Concern Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$20.9
Mkt Cap
$302.078M
52W Low
$7.78
52W High
$34.1
52W Position info
169% above low
Off High info
39% below high
Rel. Volume info
4.6× avg
Market data snapshot near publication time

GLSI has more than doubled off its 52-week low of $7.78 on elevated volume (4.6× avg).

Summary

Greenwich LifeSciences posted a $5.8 million Q3 loss, ended September with $5.9 million in cash and negative stockholders' equity, and repeated its going concern warning.


Key Events · Earnings and Guidance · GLSI

  • Q3 Loss Widens to $5.8M

    Net loss was $5,813,533 for the three months ended September 30, 2026, versus $3,711,269 a year earlier; the nine-month loss reached $15,419,345.

  • Cash Down to $5.9M

    Cash fell to $5,898,582 from $6,178,021 at December 31, 2025, while net cash used in operations was $9,620,015 for the nine months.

  • Going Concern Reiterated

    The filing states substantial doubt about the ability to continue as a going concern within one year and that continued operations depend on obtaining additional capital.

  • Negative Stockholders' Equity

    Total stockholders' equity was $(1,746,884) at September 30, 2026, down from $353,217 at December 31, 2025, as the accumulated deficit reached $102,556,351.


Analysis · GLSI · Life Sciences

Cash burn accelerated as the quarterly loss widened to $5.8 million from $3.7 million a year earlier, leaving $5.9 million on hand against a reiterated going concern warning. With stockholders' equity now negative at $(1.7) million, the balance sheet depends entirely on raising more capital. Management also concluded disclosure controls were not effective because of material weaknesses, adding reporting-error risk on top of the funding pressure.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GLSI was trading at $20.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $302.1M. The 52-week trading range was $7.78 to $34.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GLSI - Latest Insights

GLSI
Aug 11, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.55
Real-time Price: $20.90 info
Change: +$5.35 (+34%) info
Market Cap: $302.078M info
GLSI
Jul 22, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.66
Real-time Price: $20.90 info
Change: +$6.24 (+43%) info
Market Cap: $302.078M info
GLSI
Jul 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $20.69
Real-time Price: $20.90 info
Change: +$0.210 (+1%) info
Market Cap: $302.078M info
GLSI
Jul 09, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.35
Real-time Price: $20.90 info
Change: +$2.55 (+14%) info
Market Cap: $302.078M info
GLSI
Jun 04, 2026, 6:11 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $23.70
Real-time Price: $20.90 info
Change: -$2.80 (-12%) info
Market Cap: $302.078M info